海外の治験の状況「多発性骨髄腫」での検索結果
205件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Evaluation of protein expression with labeled-bevacizumab scan in patients with relapsing multiple myeloma.
- patients with relapsing multiple myeloma;Therapeutic area: Diseases [C] - Cancer [C04]
- Netherlands
- 2012-07-10
Authorised
- The use of Panobinostat, administered in combination with Velcade, Thalidomise and Dexamethasone, in subjects with relapsed and relapsed/refractory multiple myeloma.
- Multiple myeloma in the relapsed and relapsed/refractory stage MedDRA version: 14.1 Level: PT Classification code 10028228 Term: Multiple myeloma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- United Kingdom
- 2012-05-29
Authorised
- Daratumumab Open label, dose-escalation safety study in Combination with Lenalidomide and Dexamethasone in Patients with multiple myeloma
- Relapsed or Relapsed and Refractory Multiple myeloma br>MedDRA version: 20.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Denmark, France, Italy, Netherlands, United Kingdom, United States
- 2012-02-16
Authorised
- A Multicenter Open label Phase II study of Pomalidomide and Dexamethasone in Progressive Relapsed or Refractory Multiple Myeloma patients with deletion 17p or translocation (4;14) Adverse Karyotypic Abnormalities. IFM 2010-02
- This study will determine the efficacy and toxicity profile of pomalidomide and dexamethasone in patients with adverse prognostic factors as determined using adverse karyotypic abnormalities and that are in desperate need of novel therapeutics.;Therapeutic area: Diseases [C] - Cancer [C04]
- France
- 2011-05-30
Authorised
- CLINICAL STUDY FINALIZED TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD TREATMENT WITH THE LENALIDOMIDE E DEXAMETHASONE DRUGS COMPARED WITH THE DOSE REDUCTIONS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA THAT CAN NOT RECEIVE THE STANDARD CHEMIOTHERAPY
- ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS MedDRA version: 18.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2013-12-05
Authorised
- Feasibility and Efficacy of dose adjusted Melphalan – Prednisone – Bortezomib (MPV) in elderly patients = 75 years of age with newly diagnosed Multiple Myeloma; a nonrandomised phase II study
- Newly diagnosed symptomatic Multiple Myeloma br>MedDRA version: 20.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Netherlands
- 2013-07-25
Authorised
- A Multicenter Open label Phase 2 study of Carfilzomib Weekly plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma.
- A Multicenter Open label Phase 2 study of Carfilzomib Weekly plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma. br>MedDRA version: 20.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Belgium
- 2013-07-09
Authorised
- Cyclophosphamide as graft-versus-host prophylaxis after allogeneic stem cell transplantation for multiple myeloma. A phase II study.
- Multiple myeloma br>MedDRA version: 20.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000054086 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Germany
- 2017-10-09
Authorised
- Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
- Relapsed/Refractory Multiple Myeloma br>MedDRA version: 20.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000054086 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Spain
- 2017-10-02
Authorised
- A clinical study to compare the safety, effectiveness and pharmacokinetics (the way the body absorbs, distributes, and gets rid of a drug) of Daratumumab given through the subcutaneous route versus the active monitoring in patients with high risk smoldering multiple myeloma (precancerous form of blood cancer in the bone marrow)
- Smoldering multiple myeloma br>MedDRA version: 20.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000054086 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Belgium, Brazil, Canada, China, Czech Republic, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Mexico, Netherlands, Norway, Poland, Russian Federation, Spain, Sweden, Turkey, United Kingdom, United States
- 2017-09-04